In this online, self-learning activity:
Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.
In recent years molecular mechanisms contributing to TTP have been identified: patients diagnosed with TTP have larger von Willebrand factor molecules (vWF) and a defective protease enzyme of A Disintegrinlike And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13), which cleaves larger vWF molecules and inhibits platelet adhesion. In congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome), the gene that codes of ADAMTS13 is defective and cannot properly produce the enzyme, whereas in acquired TTP, antibody production leads to downstream enzymatic deactivation.
The following healthcare professionals: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.
This program is supported by an educational grant from Takeda / Shire.
Release Date: April 30, 2020 -- Expiration Date: April 30, 2022
Faculty: Satheesh Chonat, MD
Pathophysiology of TTP
Diagnosis of TTP
Clinical Manifestations or Diagnostic Opportunities
Highlights of Research Presented at ASH 2019
By the end of the session the participant will be able to:
ACCME Activity #201861263ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Satheesh Chonat M.D. , Assistant Professor, Emory University, has received financial compensation from Agios, Alexion, Amgen, and Global Therapeutics (Grants and /or Clinical Trial Funding).
Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Takeda / Shire.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Contemporary approaches to advanced diffuse large B-cell lymphoma (DLBCL)
Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies
Treating Oncology Patients During COVID-19
von Willebrand's disease (vWD): therapeutic updates and optimizing treatment